BK Virus DNA Detection and Quantification, Random, Urine
Use
The test is useful for the detection and serial monitoring of BK virus (BKV)-associated nephropathy in kidney transplant recipients, as well as BKV-associated hemorrhagic cystitis in organ transplant recipients. It helps assess the risk of BKV-associated complications in patients with kidney transplants.
Special Instructions
The assay is calibrated to the First World Health Organization International Standard for BKV DNA. Cobas PCR media contains guanidine hydrochloride and should not be allowed to contact sodium hypochlorite (bleach) or other reactive reagents. Serial monitoring of BKV DNA level in plasma is recommended to optimize immunosuppressant dosing regimens.
Limitations
Quantitative results can be up to 3.5-fold higher than previous assays due to differences in specimen extraction and target amplification. An 'Undetected' result does not rule out BKV infection; serial measurement is recommended. Carbomer-containing products may interfere with the test, generating invalid results.
FDA ApprovedNew York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
LOINC Codes
- 32285-9
- 32285-9
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
4.3 mL
Minimum Volume
Not provided
Container
cobas PCR urine tube
Collection Instructions
Collect random urine into a sterile, plastic, preservative-free container. Transfer 4.3 mL of urine into the cobas PCR urine sample tube using the disposable pipette provided within 24 hours of collection.
Storage Instructions
Transport and store urine specimen transport container at 2 to 30 degrees C (refrigerate is preferred temperature).
Causes for Rejection
Specimen evaluated at Mayo Clinic Laboratories for test suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 84 days |
| Refrigerated | 84 days |